JP2014504642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504642A5 JP2014504642A5 JP2013552619A JP2013552619A JP2014504642A5 JP 2014504642 A5 JP2014504642 A5 JP 2014504642A5 JP 2013552619 A JP2013552619 A JP 2013552619A JP 2013552619 A JP2013552619 A JP 2013552619A JP 2014504642 A5 JP2014504642 A5 JP 2014504642A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- alkyl
- replaced
- cycloalkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 75
- 208000002193 Pain Diseases 0.000 claims description 65
- 125000004122 cyclic group Chemical group 0.000 claims description 53
- 229910052760 oxygen Inorganic materials 0.000 claims description 48
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 44
- 229910052717 sulfur Inorganic materials 0.000 claims description 42
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 34
- 125000005843 halogen group Chemical group 0.000 claims description 32
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 30
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 22
- -1 CF 3 Chemical group 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 230000001154 acute effect Effects 0.000 claims description 19
- 208000004296 neuralgia Diseases 0.000 claims description 13
- 230000001684 chronic effect Effects 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 208000008035 Back Pain Diseases 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 8
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 206010027599 migraine Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 230000002981 neuropathic effect Effects 0.000 claims description 7
- 208000021722 neuropathic pain Diseases 0.000 claims description 7
- 208000009935 visceral pain Diseases 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 208000000003 Breakthrough pain Diseases 0.000 claims description 5
- 208000006561 Cluster Headache Diseases 0.000 claims description 5
- 206010019233 Headaches Diseases 0.000 claims description 5
- 206010028836 Neck pain Diseases 0.000 claims description 5
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 5
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 5
- 231100000869 headache Toxicity 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 4
- 208000004998 Abdominal Pain Diseases 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 208000007914 Labor Pain Diseases 0.000 claims description 4
- 208000004550 Postoperative Pain Diseases 0.000 claims description 4
- 108010052164 Sodium Channels Proteins 0.000 claims description 4
- 102000018674 Sodium Channels Human genes 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 206010058019 Cancer Pain Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 206010021639 Incontinence Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 3
- 208000004404 Intractable Pain Diseases 0.000 claims description 3
- 206010026749 Mania Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 206010061533 Myotonia Diseases 0.000 claims description 3
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 3
- 208000008765 Sciatica Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000015706 neuroendocrine disease Diseases 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 2
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010006002 Bone pain Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010064012 Central pain syndrome Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000024720 Fabry Disease Diseases 0.000 claims description 2
- 206010016059 Facial pain Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000035945 Labour pain Diseases 0.000 claims description 2
- 206010024229 Leprosy Diseases 0.000 claims description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 2
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 2
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 206010033557 Palpitations Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 208000000450 Pelvic Pain Diseases 0.000 claims description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 206010037779 Radiculopathy Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 206010043269 Tension headache Diseases 0.000 claims description 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 208000025609 Urogenital disease Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 208000034757 axonal type 2FF Charcot-Marie-Tooth disease Diseases 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 2
- 230000005176 gastrointestinal motility Effects 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 230000001314 paroxysmal effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000005198 spinal stenosis Diseases 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 208000026533 urinary bladder disease Diseases 0.000 claims description 2
- 208000008930 Low Back Pain Diseases 0.000 claims 2
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 206010063057 Cystitis noninfective Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 210000002414 leg Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001694 thigh bone Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 206010040037 Sensory neuropathy hereditary Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 201000006847 hereditary sensory neuropathy Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438685P | 2011-02-02 | 2011-02-02 | |
| US61/438,685 | 2011-02-02 | ||
| US201161440987P | 2011-02-09 | 2011-02-09 | |
| US61/440,987 | 2011-02-09 | ||
| US201161495538P | 2011-06-10 | 2011-06-10 | |
| US61/495,538 | 2011-06-10 | ||
| PCT/US2012/023593 WO2012106499A1 (en) | 2011-02-02 | 2012-02-02 | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015251126A Division JP6261558B2 (ja) | 2011-02-02 | 2015-12-24 | イオンチャネルのモジュレーターとしてのピロロピラジン−スピロ環式ピペリジンアミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014504642A JP2014504642A (ja) | 2014-02-24 |
| JP2014504642A5 true JP2014504642A5 (https=) | 2015-03-19 |
| JP6021824B2 JP6021824B2 (ja) | 2016-11-09 |
Family
ID=45689011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013552619A Active JP6021824B2 (ja) | 2011-02-02 | 2012-02-02 | イオンチャネルのモジュレーターとしてのピロロピラジン−スピロ環式ピペリジンアミド |
| JP2015251126A Active JP6261558B2 (ja) | 2011-02-02 | 2015-12-24 | イオンチャネルのモジュレーターとしてのピロロピラジン−スピロ環式ピペリジンアミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015251126A Active JP6261558B2 (ja) | 2011-02-02 | 2015-12-24 | イオンチャネルのモジュレーターとしてのピロロピラジン−スピロ環式ピペリジンアミド |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8916565B2 (https=) |
| EP (2) | EP2670752B1 (https=) |
| JP (2) | JP6021824B2 (https=) |
| KR (1) | KR101923367B1 (https=) |
| CN (2) | CN103403004B (https=) |
| AR (1) | AR085893A1 (https=) |
| AU (1) | AU2012212196B2 (https=) |
| BR (1) | BR112013019211A2 (https=) |
| CA (1) | CA2825204C (https=) |
| CY (1) | CY1117471T1 (https=) |
| DK (1) | DK2670752T3 (https=) |
| ES (1) | ES2573497T3 (https=) |
| HR (1) | HRP20160382T8 (https=) |
| HU (1) | HUE028789T2 (https=) |
| IL (1) | IL227815B (https=) |
| MX (1) | MX355907B (https=) |
| NZ (1) | NZ613028A (https=) |
| PL (1) | PL2670752T3 (https=) |
| PT (1) | PT2670752E (https=) |
| RS (1) | RS54785B1 (https=) |
| RU (1) | RU2634900C2 (https=) |
| SG (1) | SG192248A1 (https=) |
| SI (1) | SI2670752T1 (https=) |
| SM (1) | SMT201600162B (https=) |
| TW (2) | TW201604196A (https=) |
| WO (1) | WO2012106499A1 (https=) |
| ZA (1) | ZA201305152B (https=) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5389030B2 (ja) | 2007-08-24 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン |
| US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| MX355907B (es) * | 2011-02-02 | 2018-05-04 | Vertex Pharma | Pirrolopirazina-piperidina espirociclica-amidas como moduladores de canales de ionicos. |
| JP5940562B2 (ja) | 2011-02-18 | 2016-06-29 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド |
| MX347982B (es) | 2011-03-14 | 2017-05-22 | Vertex Pharma | Morfolina-piperidina espirociclica-amidas como moduladores de canales ionicos. |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| CN104718188B (zh) | 2012-05-22 | 2018-08-21 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
| KR101663436B1 (ko) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
| WO2014022639A1 (en) * | 2012-08-01 | 2014-02-06 | Vertex Pharmaceuticals Incorporated | Solid forms of (4-isopropoxy-3-methoxyphenyl)(2'-methyl-6'-(trifluoromethyl)-3',4'-dihydro-2'h-spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]-1-yl)methanone |
| CN105073738B (zh) | 2013-01-31 | 2018-01-05 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的喹啉及喹喔啉酰胺类 |
| KR102295748B1 (ko) | 2013-01-31 | 2021-09-01 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 피리돈 아미드 |
| WO2014134391A1 (en) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
| WO2015006280A1 (en) * | 2013-07-10 | 2015-01-15 | Vertex Pharmaceuticals Incorporated | Fused piperidine amides as modulators of ion channels |
| ES2654393T3 (es) | 2013-07-19 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Sulfonamidas como moduladores de los canales de sodio |
| WO2015078374A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| LT3080134T (lt) | 2013-12-13 | 2018-11-12 | Vertex Pharmaceuticals Incorporated | Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| HK1252567A1 (zh) | 2015-05-22 | 2019-05-31 | 基因泰克公司 | 被取代的苯甲酰胺和其使用方法 |
| JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック， インコーポレイテッド | 治療化合物及びその使用方法 |
| CA2999769A1 (en) | 2015-09-28 | 2017-04-06 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| PE20190980A1 (es) | 2016-10-17 | 2019-07-09 | Genentech Inc | Compuestos terapeuticos y metodos para utilizarlos |
| CN106749330A (zh) * | 2016-12-29 | 2017-05-31 | 长春海谱润斯科技有限公司 | 一种杂环衍生物及使用该杂环衍生物的有机发光器件 |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| US11358977B2 (en) | 2017-05-16 | 2022-06-14 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| WO2019157505A1 (en) | 2018-02-12 | 2019-08-15 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| AU2019301628C1 (en) | 2018-07-09 | 2025-02-06 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting NaV1.8 |
| AU2019302534B2 (en) | 2018-07-09 | 2024-10-03 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting NaV1.8 |
| JP7619951B2 (ja) * | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| US12441703B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| AU2020234961C1 (en) | 2019-03-11 | 2025-08-14 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CN113811305A (zh) | 2019-03-11 | 2021-12-17 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
| BR112021017809A2 (pt) | 2019-03-11 | 2021-11-23 | Nocion Therapeutics Inc | Bloqueadores de canais iônicos substituídos por éster e métodos para uso |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| WO2021091585A1 (en) | 2019-11-06 | 2021-05-14 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| WO2021091586A1 (en) | 2019-11-06 | 2021-05-14 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CA3164134A1 (en) | 2019-12-06 | 2021-06-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| US11332446B2 (en) | 2020-03-11 | 2022-05-17 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| MA64856B1 (fr) | 2021-06-04 | 2026-02-27 | Vertex Pharmaceuticals Incorporated | Formes de dosage solides et regimens de dosage comprenant le [[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl) tétrahydrofuranne-2-carbonyl]amino]pyridine-2-carboxamide |
| JP2024520643A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン |
| WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| CA3221788A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| JP2024520646A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体 |
| UY40234A (es) | 2022-04-22 | 2023-11-15 | Vertex Pharma | Compuestos heteroarilo para el tratamiento del dolor |
| JP2025513452A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| GEAP202516634A (en) | 2022-04-22 | 2025-02-25 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023391870A1 (en) | 2022-12-06 | 2025-06-05 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| CN117385378B (zh) * | 2023-10-13 | 2024-09-24 | 厦门大学 | 一种缺电子芳香缩醛的电氧化制备方法和应用 |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025122953A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| WO2025165967A2 (en) * | 2024-02-02 | 2025-08-07 | Maplight Therapeutics, Inc. | Gpr6 inverse agonists |
| CN121013715A (zh) * | 2024-03-22 | 2025-11-25 | 艾瑞克·奎因 | 镁和利多卡因组合物 |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3939159A (en) | 1974-05-29 | 1976-02-17 | American Hoechst Corporation | Spiro(pyrrolo (1,2-A)quinoxalines) |
| PT67194B (en) | 1976-11-02 | 1979-03-23 | Lilly Co Eli | Process for preparing 4a-aryl-octahydro-1h-2-pyrindines |
| NZ189230A (en) | 1977-12-27 | 1981-05-15 | Lilly Co Eli | Trans-4a-aryl-2-substituted-octahydro-1h-2-pyrindines |
| US4353901A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| GB8827479D0 (en) | 1988-11-24 | 1988-12-29 | Zambeletti Spa L | Novel compounds |
| IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| US5206240A (en) | 1989-12-08 | 1993-04-27 | Merck & Co., Inc. | Nitrogen-containing spirocycles |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| JPH04297458A (ja) | 1991-03-27 | 1992-10-21 | Toray Ind Inc | イソキノリン誘導体およびその製造方法 |
| GB9104656D0 (en) | 1991-03-05 | 1991-04-17 | Zambeletti Spa L | Pharmaceuticals |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| DE4341403A1 (de) | 1993-12-04 | 1995-06-08 | Basf Ag | N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung |
| JPH10500112A (ja) | 1994-05-06 | 1998-01-06 | ファーマコピーア，インコーポレイテッド | 組合せ ジヒドロベンゾピラン ライブラリー |
| US6017768A (en) | 1994-05-06 | 2000-01-25 | Pharmacopeia, Inc. | Combinatorial dihydrobenzopyran library |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| IT1276462B1 (it) | 1995-07-03 | 1997-10-31 | Rotta Research Lab | Diamidi aromatiche acide ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico |
| DE69633245T2 (de) | 1995-09-29 | 2005-09-08 | Eli Lilly And Co., Indianapolis | Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation |
| US20040266802A1 (en) | 1999-06-07 | 2004-12-30 | Alain Calvet | Tricyclic analgesics |
| JP2003513006A (ja) * | 1999-06-07 | 2003-04-08 | ワーナー−ランバート・カンパニー | 三環性鎮痛薬 |
| US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| AU2001289831A1 (en) | 2000-09-06 | 2002-03-22 | Bayer Aktiengesellschaft | Medicaments against viral infections |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| AU2003235912A1 (en) | 2002-05-10 | 2003-11-11 | Taisho Pharmaceutical Co., Ltd. | Spiro-ring compound |
| AU2003242092A1 (en) | 2002-06-11 | 2003-12-22 | Sankyo Company, Limited | Process for producing cyclic thioether and synthetic intermediate thereof |
| US20060052597A1 (en) | 2002-10-22 | 2006-03-09 | Best Desmond J | Aryloxyalkylamine derivatives as h3 receptor ligands |
| KR20050065613A (ko) | 2002-10-24 | 2005-06-29 | 상꾜 가부시키가이샤 | 광학 활성인 술폭시드의 제조법 |
| BR0317230A (pt) | 2002-12-13 | 2005-10-25 | Smithkline Beecham Corp | Composto, composição, métodos de antagonizar uma atividade do receptor de quimiocina ccr-5, e de tratar uma infecção viral em um paciente, e, uso de um composto |
| EP1599447A1 (en) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| JPWO2004092179A1 (ja) | 2003-04-14 | 2006-07-06 | 日本曹達株式会社 | スピロ誘導体、製造法および抗酸化薬 |
| FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| CN101921279A (zh) | 2003-10-01 | 2010-12-22 | 阿得罗公司 | 螺环杂环衍生物及其应用方法 |
| EP1679069A4 (en) | 2003-10-21 | 2009-05-13 | Dainippon Sumitomo Pharma Co | NEW PIPERIDINE DERIVATIVE |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| WO2005121090A1 (en) | 2004-06-02 | 2005-12-22 | Abbott Laboratories | Substituted piperidines that have antiangiogenic activity |
| US7598261B2 (en) | 2005-03-31 | 2009-10-06 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
| JP2008540395A (ja) | 2005-05-03 | 2008-11-20 | ファイザー・インク | アミドレソルシノール化合物 |
| WO2007050124A1 (en) | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| MX2008000966A (es) | 2005-07-19 | 2008-03-26 | Merck & Co Inc | Nuevos derivados de espirocromanona. |
| WO2007038138A2 (en) | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| WO2007058322A1 (ja) | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
| CN101360750A (zh) * | 2005-11-23 | 2009-02-04 | 英特芒尼公司 | 应激活化蛋白激酶系统的调节方法 |
| US20080027072A1 (en) | 2006-04-20 | 2008-01-31 | Ampla Pharmaceuticals, Inc. | Potentiation of MC4 receptor activity |
| JP2009536175A (ja) | 2006-05-05 | 2009-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特定の細胞サイクル酵素の阻害剤としてのスピロ−（ｔｈｏ）ベンゾピラン−２，４’−ピペリジン−及びシクロヘキサン誘導体 |
| EP2042503B1 (en) | 2006-05-16 | 2013-01-30 | Ono Pharmaceutical Co., Ltd. | Compound having acidic group which may be protected, and use thereof |
| CA2651681A1 (en) | 2006-05-18 | 2007-11-29 | Merck & Co., Inc. | Aryl-fused spirocyclic compounds |
| WO2008016006A1 (fr) | 2006-07-31 | 2008-02-07 | Ono Pharmaceutical Co., Ltd. | Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation |
| WO2008033299A2 (en) | 2006-09-12 | 2008-03-20 | Adolor Corporation | Use of n-containing spirocompounds for the enhancement of cognitive function |
| CL2007002958A1 (es) | 2006-10-12 | 2008-05-09 | Epix Delaware Inc | Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr |
| EA200900613A1 (ru) | 2006-11-29 | 2009-10-30 | Пфайзер Продактс Инк. | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз |
| US7501432B2 (en) * | 2006-12-22 | 2009-03-10 | Hoffman-La Roche Inc. | Spiro-piperidine derivatives |
| PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| WO2008088692A2 (en) | 2007-01-12 | 2008-07-24 | Merck & Co., Inc. | Spirochromanon derivatives |
| EP2123652A1 (en) | 2007-02-20 | 2009-11-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP2110377A1 (en) | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| WO2009144554A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Pyrazolospiroketone acetyl-c0a carboxylase inhibitors |
| CA2729412A1 (en) | 2008-07-04 | 2010-01-07 | Banyu Pharmaceutical Co., Ltd. | Novel spirochromanone carboxylic acids |
| US8822480B2 (en) | 2008-07-16 | 2014-09-02 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators |
| US20110166124A1 (en) | 2008-07-23 | 2011-07-07 | Mccormick Kevin D | Tricyclic spirocycle derivatives and methods of use |
| WO2010051497A1 (en) | 2008-10-31 | 2010-05-06 | Pain Therapeutics, Inc. | Filamin a binding anti-inflammatory and analgesic |
| EP2498600B1 (en) | 2008-10-31 | 2016-03-02 | Pain Therapeutics, Inc. | Filamin a-binding anti-inflammatory analgesic |
| EP2414348B1 (en) | 2009-04-03 | 2013-11-20 | Merck Sharp & Dohme Corp. | Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders |
| WO2010151597A1 (en) | 2009-06-26 | 2010-12-29 | Schering Corporation | Methods for using pyrrolo-benzo-1,4-diazines as sodium channel blockers |
| US8354403B2 (en) | 2009-08-27 | 2013-01-15 | Merck Sharp & Dohme Corp. | Pyrrolidine derived beta 3 adrenergic receptor agonists |
| US8633183B2 (en) | 2010-01-26 | 2014-01-21 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| MX355907B (es) * | 2011-02-02 | 2018-05-04 | Vertex Pharma | Pirrolopirazina-piperidina espirociclica-amidas como moduladores de canales de ionicos. |
| JP5940562B2 (ja) | 2011-02-18 | 2016-06-29 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド |
| MX347982B (es) | 2011-03-14 | 2017-05-22 | Vertex Pharma | Morfolina-piperidina espirociclica-amidas como moduladores de canales ionicos. |
-
2012
- 2012-02-02 MX MX2013008902A patent/MX355907B/es active IP Right Grant
- 2012-02-02 HU HUE12704985A patent/HUE028789T2/en unknown
- 2012-02-02 US US13/364,586 patent/US8916565B2/en active Active
- 2012-02-02 TW TW104136101A patent/TW201604196A/zh unknown
- 2012-02-02 SG SG2013058391A patent/SG192248A1/en unknown
- 2012-02-02 TW TW101103408A patent/TWI520964B/zh not_active IP Right Cessation
- 2012-02-02 RS RS20160229A patent/RS54785B1/sr unknown
- 2012-02-02 CN CN201280011207.8A patent/CN103403004B/zh not_active Expired - Fee Related
- 2012-02-02 AU AU2012212196A patent/AU2012212196B2/en not_active Ceased
- 2012-02-02 HR HRP20160382TT patent/HRP20160382T8/hr unknown
- 2012-02-02 WO PCT/US2012/023593 patent/WO2012106499A1/en not_active Ceased
- 2012-02-02 ES ES12704985.6T patent/ES2573497T3/es active Active
- 2012-02-02 SI SI201230587A patent/SI2670752T1/sl unknown
- 2012-02-02 JP JP2013552619A patent/JP6021824B2/ja active Active
- 2012-02-02 DK DK12704985.6T patent/DK2670752T3/en active
- 2012-02-02 BR BR112013019211A patent/BR112013019211A2/pt not_active Application Discontinuation
- 2012-02-02 AR ARP120100346A patent/AR085893A1/es active IP Right Grant
- 2012-02-02 CA CA2825204A patent/CA2825204C/en active Active
- 2012-02-02 EP EP12704985.6A patent/EP2670752B1/en active Active
- 2012-02-02 CN CN201610319591.8A patent/CN106008504A/zh active Pending
- 2012-02-02 EP EP15196033.3A patent/EP3056495A1/en not_active Withdrawn
- 2012-02-02 PL PL12704985.6T patent/PL2670752T3/pl unknown
- 2012-02-02 KR KR1020137023136A patent/KR101923367B1/ko active Active
- 2012-02-02 RU RU2013140401A patent/RU2634900C2/ru active
- 2012-02-02 NZ NZ613028A patent/NZ613028A/en not_active IP Right Cessation
- 2012-02-02 PT PT127049856T patent/PT2670752E/pt unknown
-
2013
- 2013-07-09 ZA ZA2013/05152A patent/ZA201305152B/en unknown
- 2013-08-01 IL IL227815A patent/IL227815B/en active IP Right Grant
-
2014
- 2014-12-22 US US14/578,628 patent/US9511067B2/en active Active
-
2015
- 2015-12-24 JP JP2015251126A patent/JP6261558B2/ja active Active
-
2016
- 2016-05-09 CY CY20161100381T patent/CY1117471T1/el unknown
- 2016-06-08 SM SM201600162T patent/SMT201600162B/it unknown
- 2016-12-05 US US15/369,029 patent/US20170145011A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014504642A5 (https=) | ||
| JP2014508756A5 (https=) | ||
| JP2014508169A5 (https=) | ||
| RU2016104080A (ru) | Амиды конденсированного пиперидина в качестве модуляторов ионных каналов | |
| JP2011526919A5 (https=) | ||
| JP2010528035A5 (https=) | ||
| JP2015505321A5 (https=) | ||
| EP4578852A1 (en) | Heterocyclic compound, method for preparing same, and pharmaceutical use thereof | |
| JP2010539244A5 (https=) | ||
| RU2007145434A (ru) | Бициклические производные в качестве модуляторов ионных каналов | |
| JP2011500598A5 (https=) | ||
| RU2009100159A (ru) | Тиенопирамидины, полезные в качестве модуляторов ионных каналов | |
| RU2007111897A (ru) | Хиназолины, полезные в качестве модуляторов ионных каналов перекрестные ссылки на родственные заявки | |
| JP2016526571A5 (https=) | ||
| ES2686097T3 (es) | Compuestos pirazolopirimidina | |
| BR112021002327A2 (pt) | derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4,5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3h)-ona e compostos relacionados como inibidores de ptpn11(shp2) para o tratamento do câncer | |
| KR102762016B1 (ko) | 니트록솔린 전구약물 및 이의 용도 | |
| RU2019126455A (ru) | Пиридиновые соединения в качестве аллостерических ингибиторов shp2 | |
| RU2016151727A (ru) | Нейроактивные стероиды, композиции и их применения | |
| JP2013503139A5 (https=) | ||
| JP2011503112A5 (https=) | ||
| KR20080039508A (ko) | 인데노이소퀴놀리논 유사체 및 이의 사용 방법 | |
| JP2020516591A (ja) | Ｍｏｒアゴニストおよびｋｏｒアゴニストを含有する医薬組成物、およびその用途 | |
| KR20150082606A (ko) | 겜시타빈 전구약물 및 그의 용도 | |
| RU2010123876A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов |